4.2 Review

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision

Journal

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
Volume 9, Issue 4, Pages 248-312

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/15622970802465807

Keywords

Anticonvulsants; antidepressants; antipsychotics; anxiety disorders; anxiolytics; benzodiazepines; cognitive behaviour therapy; evidence-based guidelines; generalized anxiety disorder; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; simple phobia; social phobia; SSRI; SNRI; treatment

Categories

Funding

  1. Glaxo-Smith Kline
  2. Jazz
  3. Lundbeck
  4. Pfizer
  5. Servier
  6. Teva
  7. Wyeth
  8. Abbott BMS
  9. Janssen
  10. Nastech
  11. Neuropharm
  12. AstraZeneca
  13. Bristol-Myers Squibb
  14. CSC
  15. Eli Lilly
  16. Janssen Pharmaceutica
  17. LundbeckNovartis
  18. Organon
  19. Pierre Fabre
  20. Schwabe
  21. Sepracor
  22. Janssen Cilag

Ask authors/readers for more resources

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available